Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Ranivisio (ranibizumab) is indicated for the treatment of neovascular (wet) age-related macular degeneration, treatment of visual impairment due to diabetic macular oedema or choroidal neovascularization, proliferative diabetic retinopathy, as well as vi...
Brand Name : Ranivisio
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 29, 2022
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
United Kingdom First to Grant Licence for Teva’s Ophthalmology Biosimilar Ongavia (ranibizumab)
Details : MHRA granted a licence for Ongavia® (ranibizumab), a biosimilar to Lucentis®*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic macular oedema and proliferative diabetic retinopathy.
Brand Name : Ongavia
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Formycon
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FYB201 (Ranibizumab) is used in treatment of various eye diseases in adults which cause damage to retina, thereby impairing vision. In these diseases, protein called VEGF causes excessive blood vessels to form within retina, resulting in a progressive lo...
Brand Name : FYB201
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 06, 2021
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Formycon
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Recipient : Formycon
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference product Stelara(R) in terms of efficacy, safety and immunogenicity in patients with moderate to severe psoriasis vulgari...
Brand Name : FYB202
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 09, 2020
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Recipient : Formycon
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?